OncoLink Cancer Treatment and Resources

Impact of TNM Stage on Survival and Disease Control in Adjuvant Rectal Cancer Pooled Analysis



Heather Jones, MD
University of Pennsylvania Cancer Center
Last Modified: November 4, 2001

Presenter: L.L. Gunderson
Affiliation: Institution: Oncology, Mayo Clinic, Rochester, MN

Background
This study attempts to evaluate the TMN staging and the MAC staging as predictors of outcome such as overall survival and patterns of failure for patients with rectal cancer who have undergone adjuvant therapy. The study evaluates patients from 3 randomized studies in North America.

Materials and Methods

  • Eligible patients on NCCTG 79-47-51 (N=200), NCCTG 86-47-51 (N=656) and INT 114 (N=1695) had data merged for analysis.
  • All patients received postop radiation (RT) and 96% were randomized to receive concomitant and maintenance chemotherapy (CT).
  • 5yr follow-up was available in 94% of patients and 7yr FU in 84%.
  • Overall and disease-free survival (OS, DFS) and time to local and distant relapse were estimated using cumulative incidence methodology.

    Results

  • Both OS and DFS were dependent on TN stage Three risk groups of patients were defined: 1) intermediate- T3N0, T1-2N1 2) moderately high- T4N0, T1-2N2, T3N1 and 3) high- T3N2, T4N1, T4N2.
  • For Group 1, 5yr OS was 74% and 81% and 5yr DFS 66% and 74%
  • For Group 2, 5yr OS ranged from 61% to 69%
  • For Group 3, 5 yr OS ranged from 33% to 48%
  • Similar differences by TN stage were seen for cumulative incidence rates of local relapse and distant metastases

    Author's Conclusions
    Patients with only a single high-risk factor of either extension beyond the rectal wall or nodal involvement have improved OS, DFS and disease control when compared to those with both high risk factors. For the purposes of future trial design, it may be appropriate to perform separate studies for the "intermediate risk" subsets of T3N0 and T1-2N1 vs the "moderately high" or "high risk" subsets in view of differential survival and rates of relapse.

    Clinical/Scientific Implications
    This is a very interesting study that would seem to indicate that the TMN and MAC are not clear prognostic indicators of functional outcome as previously believed. Even more interesting is the independent prognostic factor of T stage in the Nodal groups. This study clearly demonstrates that there is a selective group of N2 patients with disease confined to the rectal wall that has better overall survival and disease- free survival than traditionally would be predicted.

  • OncoLink I wish u knew...

    Survivorship care can help cancer survivors live healthier, fuller lives after treatment. Read more.

    Cancer Types
    Bone Cancer
    Brain Tumors
    Breast Cancer
    Carcinoid Tumors
    Endocrine System Cancers
    Gastrointestinal Cancers
    Gynecologic Cancers
    Head and Neck Cancers
    Leukemia
    Lung Cancers
    Lymphomas
    Myelomas
    Pediatric Cancers
    Penile Cancer
    Prostate Cancer
    Sarcomas
    Skin Cancers
    Testicular Cancer
    Thyroid Cancer
    Urinary Tract Cancers
    OncoLink Vet

    Cancer Treatment
    Biologic Therapy
    Bone Marrow Transplants
    Chemotherapy

    Clinical Trials
    Complementary Medicine
    Gene Therapy
    General Treatment Concerns
    Hormone Therapy
    PDT Center
    Proton Therapy
    Radiation Oncology
    Surgical Oncology
    Targeted Therapies
    Vaccine Therapies

    Cancer Support
    Caregivers
    Hospice Care and Bereavement
    Nutrition and Cancer
    Sexuality & Fertility
    Side Effects
    Support
    Survivorship
    Exercise and Cancer

    Cancer Resources
    Cancer News
    OncoLink University
    Nurses' Notes
    Conferences
    Newly Diagnosed Patients
    Causes and Prevention
    Legal and Financial Information for Patients
    LGBT Resources
    NCI Resources
    Global Resources
    Cancer Resource List
    Resources for Young Adults

    OncoLink Media Library
    OncoLink TV
    Book, Music and Video Reviews


    Ask the Experts
    Brown Bag Chat
    Tracy's Corner

    About OncoLink
    About OncoLink
    Giving to OncoLink
    Contact Information
    Usage Policy
    Editorial Board
    How to Partner with OncoLink
    Link to OncoLink
    Mission Statement

    OncoLink Cancer Resources RSS What's New RSS